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Psoriatic arthritis
Key messages
What is already known about this subject?
 ► enthesitis and dactylitis are core features of psoriat-
ic arthritis (Psa) that are difficult to treat and impact 
the overall severity and burden of disease.
 ► apremilast, an oral small molecule that inhibits 
phosphodiesterase 4, has been shown to be effec-
tive in the treatment of Psa in the Psoriatic arthritis 
long-term assessment of clinical efficacy (Palace) 
clinical trial programme; however, the individual 
studies were not designed to obtain meaningful con-
clusions for patients with enthesitis and/or dactylitis.
What does this study add?
 ► the findings of this pooled analysis of data from 
the Palace studies provide long-term data demon-
strating the effectiveness of apremilast in improving 
enthesitis and dactylitis in patients with active Psa.
How might this impact on clinical practice?
 ► apremilast provides an effective treatment option for 
the long-term treatment of enthesitis and dactylitis 
in patients with active Psa.
AbstrAct
Objective the Psoriatic arthritis long-term assessment of 
clinical efficacy (Palace) clinical trial programme findings 
demonstrated that apremilast, an oral phosphodiesterase 
4 inhibitor, is effective for treating psoriatic arthritis (Psa). 
enthesitis and dactylitis are difficult-to-treat features 
of Psa leading to disability and affecting quality of life. 
Palace 1, 2 and 3 data were pooled to assess the efficacy 
of apremilast on enthesitis and dactylitis outcomes in 
patients with these conditions at baseline.
Methods Patients with enthesitis (n=945) or dactylitis 
(n=633) at baseline were analysed after receiving double-
blind treatment with placebo, apremilast 30 mg two 
times per day or apremilast 20 mg two times per day up 
to 52 weeks and continuing up to 5 years. Data were 
analysed through 156 weeks. enthesitis was evaluated 
by Maastricht ankylosing Spondylitis enthesitis Score 
(MaSeS) and dactylitis via dactylitis count.
Results at week 24, patients receiving apremilast 30 mg 
two times per day demonstrated a significantly greater 
mean change in enthesitis (−1.3 vs −0.9; p<0.05) and 
dactylitis (−1.8 vs −1.3; p<0.01) vs placebo. Patients 
in the 30 mg dose group showed significantly greater 
mean (−23.6% vs −7.0%; p<0.05) and median (−50.0% 
vs −21.1%; p<0.05) per cent changes in MaSeS; mean 
and median per cent changes in dactylitis count were 
numerically, but not significantly, different for either 
apremilast dose in patients with dactylitis. in the patient 
population remaining on apremilast, observed mean and 
median improvements in both conditions were sustained 
through 156 weeks.
Conclusion apremilast is effective for the treatment 
of active Psa, including improvements in enthesitis and 
dactylitis up to 3 years.
Trial registration numbers nct01172938, 
nct01212757 and nct01212770.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic inflamma-
tory disease that is remarkably diverse in pres-
entation and course and is characterised by 
the presence of peripheral arthritis, psoriasis, 
enthesitis, dactylitis and spondylitis as well 
as skin and nail manifestations.1–3 Enthesitis 
and dactylitis are distinguishing features of 
PsA that may be associated with more severe 
disease; both conditions can be difficult to 
treat, lead to disability and negatively impact 
quality of life.2 4–8 Current therapeutic options 
for PsA include systemic therapy with conven-
tional disease-modifying antirheumatic drugs 
(DMARDs) or biological agents; however, to 
date, there is little evidence of the efficacy 
of conventional DMARDs in enthesitis or 
dactylitis in PsA.9 
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Apremilast is an oral phosphodiesterase 4 inhibitor 
that helps regulate the aberrant immune response in 
PsA that causes joint symptoms, enthesitis, dactylitis, 
systemic inflammation and skin disease.1 10 The efficacy 
and safety of apremilast in PsA are being evaluated in the 
Psoriatic Arthritis Long-term Assessment of Clinical Effi-
cacy (PALACE) clinical trial programme. The PALACE 
1, 2 and 3 studies are assessing the efficacy and safety 
of apremilast in patients with active PsA despite prior 
conventional DMARDs and/or biological therapy. This 
programme has collected a large dataset for patients 
with PsA, allowing for comprehensive analyses of many 
aspects of treatment outcomes. Results from all three 
PALACE studies demonstrated that apremilast is effec-
tive in reducing the signs and symptoms of PsA and in 
improving physical function.11–14 
Although the impact of apremilast treatment on 
enthesitis and dactylitis was evaluated in each of the 
PALACE studies, the presence of these conditions was 
not required for inclusion, and the studies were not 
specifically designed to obtain meaningful conclusions 
for patients with enthesitis and/or dactylitis. Therefore, 
to assess short-term and long-term outcomes in a broad 
population of patients with enthesitis and/or dactylitis 
who entered PALACE 1, 2 and 3, a pooled analysis of data 
from these patients in all three studies was conducted 
to evaluate the therapeutic benefit of apremilast for 
enthesitis and dactylitis over 156 weeks.
MeTHOds
study design
PALACE 1, 2 and 3 (NCT01172938, NCT01212757 and 
NCT01212770) are phase III, multicentre, randomised, 
double-blind, placebo-controlled clinical trials with 
similar designs, which were previously described in 
detail.11–14 Briefly, patients were randomised (1:1:1) to 
receive placebo, apremilast 30 mg two times per day or 
apremilast 20 mg two times per day, stratified by base-
line DMARD use (yes/no) and, in PALACE 3 only, by 
baseline psoriasis involvement of the body surface area 
(<3%/≥3%; online supplementary figure 1). Patients 
whose swollen and tender joint counts had not improved 
by ≥20% at week 16 were considered non-responders and 
continued on their initial apremilast dose or, if initially 
randomised to placebo, were randomised (1:1) to receive 
apremilast 30 mg two times per day or 20 mg two times 
per day (early escape). At week 24, all remaining patients 
on placebo were switched to apremilast 30 mg or 20 mg 
two times per day. On completion of the 52 week, double-
blind period, patients were eligible to enter a long-term 
treatment phase for a total follow-up of up to 5 years.
study population
All patients provided written informed consent prior 
to study initiation. Detailed inclusion and exclusion 
criteria for the PALACE studies have been published 
elsewhere.11 13 14 Briefly, adult patients required a 
diagnosis of PsA for ≥6 months, met the Classification 
Criteria for Psoriatic Arthritis (CASPAR) at study entry 
and were required to have three or more swollen joints 
and three or more tender joints at baseline. All patients 
were required to have had current or prior therapy with 
DMARDs and/or biological agents; however, they were 
ineligible for study inclusion if they experienced thera-
peutic failure of more than three DMARDs or biologi-
cals or more than one tumour necrosis factor blocker. 
In addition, one or more plaque psoriasis lesions that 
were ≥2 cm was required in PALACE 3. The focus of the 
current analysis is patients who had enthesitis or dactylitis 
at baseline. Limited analyses were conducted in patients 
without enthesitis or dactylitis at baseline to examine the 
development of these manifestations during 24 weeks.
Concomitant therapy of any combination of meth-
otrexate (≤25 mg/week), leflunomide (≤20 mg/day), 
sulfasalazine (≤2 g/day) with a stable dose for at least 
16 weeks prior to screening was permitted during the 
study, with one DMARD dose reduction allowed between 
weeks 24 and 52. Stable doses of non-steroidal anti-in-
flammatory drugs for ≥2 weeks or oral corticosteroids 
(prednisone ≤10 mg or equivalent) for ≥1 month prior 
to screening were allowed.
efficacy assessments
Enthesitis and dactylitis were clinically evaluated at base-
line and at weeks 16, 24, 52, 65, 78, 91, 104, 117, 130, 143 
and 156 (or at early termination/withdrawal). The assess-
ments of enthesitis and dactylitis in PsA were proven to 
be reliable in the INSPIRE study.15 
Enthesitis in the current analysis was evaluated in 
patients who had enthesitis at baseline, defined as a Maas-
tricht Ankylosing Spondylitis Enthesitis Score (MASES) 
>0. The MASES determines the presence or absence of 
pain at 13 select entheses/tendon insertions,16 with scores 
ranging from 0 to 13. Enthesitis outcomes included the 
change and per cent change in MASES from baseline and 
achievement of a MASES of 0 (no pain at any assessed 
entheses).
Dactylitis was evaluated in patients with a dactylitis 
count >0 at baseline, reflecting the presence (score=1) or 
absence (score=0) of dactylitis in each of the 20 digits (the 
possible dactylitis count ranges from 0 to 20). Dactylitis 
outcomes included the change and per cent change 
from baseline in dactylitis count and achievement of a 
dactylitis count of 0, indicating the absence of dactylitis 
on all 20 digits.
statistical analysis
Data from PALACE 1, 2 and 3 were pooled in a prespec-
ified analysis, permitting a robust analysis of data for all 
randomised patients with pre-existing enthesitis (base-
line MASES>0) and/or dactylitis (baseline dactylitis 
count >0) who received one or more doses of study medi-
cation. Changes and per cent changes from baseline in 
MASES and dactylitis count at week 24 were prespecified 
and analysed using an analysis of covariance model with 
 o
n
 20 August 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000669 on 27 June 2018. Downloaded from
 
3gladman DD, et al. RMD Open 2018;4:e000669. doi:10.1136/rmdopen-2018-000669
Psoriatic arthritis
treatment, baseline DMARD use (yes/no) and study as 
factors and the baseline value as a covariate. Per cent 
changes from baseline were also analysed using rank 
transformation, with the same analysis model. Missing 
values were handled using the last-observation-car-
ried-forward (LOCF) methodology. Specifically, for 
patients who entered early escape at week 16, the week 16 
value was carried forward to week 24; for other patients, 
the last postbaseline value was carried forward if the week 
24 value was missing. Analyses at week 52 were prespeci-
fied and analyses at weeks 104 and 156 were posthoc; all 
long-term analyses are based on data as observed. Data 
from all patients with enthesitis or dactylitis at baseline 
were analysed descriptively through week 156, regardless 
of when patients started treatment with apremilast (base-
line, week 16 or week 24).
ResulTs
Patient characteristics
Across PALACE 1, 2 and 3, 63.3% (945/1493) of patients 
had enthesitis and 42.4% (633/1493) had dactylitis at 
baseline and were included in the current analysis. Base-
line patient demographics, disease characteristics and 
prior and concurrent therapy were comparable across 
treatment groups (table 1). Baseline mean MASES 
(range 4.5–4.8) and dactylitis counts (range 3.2–3.4) 
were also similar across treatment groups among patients 
with enthesitis and dactylitis, respectively.
efficacy results: enthesitis
At week 24, patients treated with apremilast 30 mg 
two times per day demonstrated a significantly greater 
mean change from baseline in enthesitis compared with 
placebo (p=0.02) (table 2). Moreover, apremilast 30 mg 
two times per day resulted in significantly greater mean 
and median per cent changes in MASES from baseline 
compared with placebo (table 2). Among patients treated 
with either apremilast 30 mg twice daily or 20 mg twice 
daily, numerically greater improvements in enthesitis and 
in proportions of patients achieving a MASES of 0 were 
observed compared with placebo at week 24 (table 2). In 
the population of patients continuing apremilast 30 mg 
two times per day or 20 mg two times per day through 
3 years, mean and median improvements in MASES 
were sustained. Specifically, at week 156, mean changes 
from baseline were −2.7 (30 mg two times per day) and 
−2.8 (20 mg two times per day) (table 2). Mean per cent 
changes from baseline were −65.2% (30 mg two times per 
day) and −57.6% (20 mg two times per day; figure 1A) 
and median per cent changes were −100% for both treat-
ment groups (table 2). At week 156, 55.0% of patients 
treated with apremilast 30 mg two times per day and 
55.1% treated with apremilast 20 mg two times per day 
achieved a MASES of 0 (figure 1B). When looking at the 
development of enthesitis over time in patients with a 
MASES of 0 at baseline, almost twice as many placebo 
patients (32.7%) with a MASES of 0 at baseline developed 
enthesitis at week 24 than patients treated with apremi-
last 30 mg two times per day (18.4%) or 20 mg two times 
per day (18.2%).
efficacy results: dactylitis
At week 24, mean dactylitis count was significantly 
improved from baseline in patients treated with apremi-
last 30 mg two times per day compared with placebo 
(p≤0.01). Mean and median per cent changes from 
baseline were not significantly different in either dose 
group compared with placebo; however, the median 
per cent change from baseline in the 30 mg dose group 
trended toward statistical significance vs placebo (p=0.06; 
table 3). The difference in the proportion of patients 
achieving a dactylitis count of 0 was not statistically signif-
icant (table 3).
In the population of patients continuing apremilast 
treatment through 3 years, mean and median improve-
ments in dactylitis count were sustained (figure 2A; 
table 3). Specifically, at week 156, mean changes from 
baseline were −3.0 (30 mg two times per day) and −2.4 
(20 mg two times per day). Mean per cent changes in 
dactylitis count were −83.6% (30 mg two times per day) 
and −73.4% (20 mg two times per day; figure 2A) and 
median per cent changes from baseline at week 156 were 
−100.0% for both dose groups (table 3). At week 156, 
79.6% of patients treated with apremilast 30 mg two times 
per day and 73.9% treated with apremilast 20 mg two 
times per day achieved a dactylitis count of 0 (figure 2B). 
Among patients with a dactylitis count of 0 at baseline, 
approximately twofold as many patients receiving placebo 
(15.8%) developed dactylitis versus patients treated with 
apremilast 30 mg two times per day (8.3%) or apremilast 
20 mg two times per day (7.0%) at week 24.
dIsCussIOn
When assessing new therapies for the treatment of PsA, 
it is important to understand the impact treatment 
has on hallmark features of PsA such as enthesitis and 
dactylitis.9 17–21 These conditions often occur in the lower 
extremities and may cause tenderness or pain while 
standing and walking4 5 7 as well as limit the ability to 
hold or grasp objects and affect fine motor function.4 22 
Overall, they are associated with impaired function, may 
negatively impact quality of life and are difficult to treat 
using conventional treatments.4–8 Both enthesitis and 
dactylitis also significantly contribute to the perceived 
burden of disease among patients with PsA.23 Dactylitis is 
actually considered a marker of PsA disease severity.7 24 25 
It is also noteworthy that there is little evidence suggesting 
conventional DMARDs are effective in treating either 
enthesitis or dactylitis.9 
The results from our pooled analysis of patients with 
enthesitis and/or dactylitis at baseline in the PALACE 
1, 2 and 3 studies showed that apremilast is effective in 
reducing the severity of both conditions in the popu-
lation of patients remaining on apremilast through 
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d
3 years of treatment. At baseline, nearly two-thirds of 
enrolled patients had enthesitis and approximately half 
had dactylitis in one or more digits. By week 24, statis-
tically significant improvements in enthesitis (mean, 
mean per cent and median per cent changes) were 
observed after treatment with apremilast 30 mg two 
times per day. Although mean and median per cent 
improvements in dactylitis were not significant, apremi-
last 30 mg two times per day showed a strong trend 
towards improvement versus placebo (median per cent 
change, −79.3% vs −66.7%; p=0.06), and the mean 
change in dactylitis count at week 24 was significant 
and sustained through 156 weeks in the population of 
patients continuing treatment. Despite the pooling of 
the three studies, the number of patients in the analysis 
is relatively small.
It is also noteworthy that patients who were treated 
with apremilast showed improvements in enthesitis and 
dactylitis already present at baseline  and demonstrated 
lower rates of onset of these conditions during the study. 
Specifically, among patients with a MASES of 0 at base-
line, about twice as many patients receiving placebo 
developed enthesitis versus patients treated with apremi-
last 30 mg two times per day (32.7% vs 18.4%) at week 24. 
Among the subgroup of patients who entered early escape 
(failed to achieve ≥20% improvement in swollen and 
tender joint counts at week 16), a comparable number of 
placebo versus apremilast patients developed enthesitis 
(39.3% vs 41.5%). Among patients with a dactylitis count 
of 0 at baseline, almost twofold as many patients receiving 
placebo developed dactylitis versus patients treated with 
apremilast 30 mg two times per day (15.8% vs 8.3%) at 
week 24. Similarly, of those patients who entered early 
escape, nearly twice as many patients receiving placebo 
developed dactylitis versus patients treated with apremi-
last (21.5% vs 12.6%).
Previous analyses of PALACE data from weeks 16 and 24 
did not detect consistent, significantly greater improve-
ments in enthesitis or dactylitis with apremilast versus 
placebo in all studies.11 14 This might be partially due to 
insufficient numbers of patients with these conditions at 
baseline to yield adequate power to detect differences 
between treatment groups. We believe that this pooled 
analysis helps to address these challenges, yielding 
greater power to detect changes in enthesitis or dactylitis 
than in the individual PALACE studies; however, this still 
may not be enough.
This study had several limitations. First, long-term 
results were posthoc analyses of mean and median 
changes in a population of patients continuing treat-
ment in the PALACE studies, which were not originally 
designed nor powered to investigate outcomes relating 
to enthesitis and dactylitis. Second, in recognising the 
heterogeneity in the instruments used to evaluate and 
interpret enthesitis and dactylitis measures,20 26 we 
understand that the MASES was designed for patients 
with ankylosing spondylitis where sites of interest are 
more central and may not be ideal for evaluating the 
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Figure 1  (A) Mean per cent change in MASES up to week 156 and (B) patients achieving a MASES of 0 up to week 156. 
Data as observed in patients with pre-existing enthesitis. Analyses include all patient data, including the placebo-controlled 
period, regardless of when patients started taking apremilast (baseline, week 16 or week 24). MASES, Maastricht Ankylosing 
Spondylitis Enthesitis Score; n/m, number of responders/number of patients with sufficient data for evaluation.
more characteristically peripheral sites of interest in 
PsA.27 In future studies, scales such as the Spondyloar-
thritis Research Consortium of Canada enthesitis index 
or Leeds Enthesitis Index that evaluate peripheral 
enthesitis sites may be more appropriate for patients 
with PsA.15 27 Third, this study did not assess the impact 
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Figure 2  (A) Mean per cent change in dactylitis up to week 156 and (B) patients achieving a dactylitis count of 0 up to week 
156. Data as observed in patients with pre-existing dactylitis. Analyses include all patient data, including the placebo-controlled 
period, regardless of when patients started taking apremilast (baseline, week 16 or week 24). n/m, number of responders/
number of patients with sufficient data for evaluation.
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of apremilast on patients with acute versus chronic 
dactylitis; rather, the analysis took a binary approach to 
determine whether the condition was merely present 
or absent. The mean dactylitis count at baseline was 
associated with a limited dynamic range (3.2–3.4), 
which may have limited our ability to detect differences 
between apremilast and placebo. This contrasts with 
methods based on the grading of dactylitis severity for 
each digit, as used in the GO-REVEAL study with golim-
umab (0=no dactylitis; 3=severe dactylitis; range 0–60)28 
or based on the size and tenderness of each digit with 
dactylitis (Leeds Dactylitis Instrument),29 as used in the 
RAPID-PsA study.30 These methods may be associated 
with greater sensitivity to detect changes between active 
therapies and placebo.
Our analysis may have also been limited by the fact 
that improvements observed in placebo patients in the 
initial PALACE studies were somewhat greater than those 
observed in studies with other agents,31 32 potentially 
reducing the observed therapeutic effect of apremilast. 
The observed level of improvement in enthesitis and 
dactylitis among placebo patients was unexpected and 
not explained by baseline differences between groups in 
symptom severity, which was generally similar between 
treatment groups. The ability to detect enthesitis and 
dactylitis improvement following treatment may have 
been differentially impacted by the natural course and 
variation of the symptoms evaluated. For example, 
improvements among patients with enthesitis receiving 
placebo may be partially explained by previous evidence, 
suggesting this condition may naturally improve over 
time, regardless of treatment.6 8 
In conclusion, enthesitis and dactylitis are core 
features of PsA that have an important impact on overall 
severity and burden of disease. In this analysis of patients 
continuing apremilast treatment, we observed improve-
ments in the difficult-to-treat manifestations of PsA, 
enthesitis and dactylitis, up to 3 years.
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